PTO/SB/08a (03-08)
Approved for use through 06/30/2008 OMB 0651-0031
U S Patent and Trademark Office, U S DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10642844
Filing Date	2003-08-18
First Named Inventor	Lewy
Art Unit	1614
Examiner Name	Royds, Leslie A.
Attorney Docket Number	90-559-T

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1							☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10642844
	Filing Date	2003-08-18
	First Named Inventor	Lewy
	Art Unit	1614
	Examiner Name	Royds, Leslie A.
	Attorney Docket Number	90-559-T

	1	ARAI et al. "Isoflurane increases, but sevoflurane decreases blood concentrations of melatonin in women," Journal of Anesthesiology 18(3):228-31 (2004).	☐
	2	DAVIES et al. "Mapping the Melatonin Receptor. 5. Melatonin Agonists and Antagonists Derived from Tetrahydrocyclopent[b]indoles, Tetrahydrocarbazoles and Hexahydro cyclopent[b]indoles," Journal of Medicinal Chemistry 41(4):451-67 (1998).	☐
	3	DEMISCH "Melatonin and cortisol increase after fluvoxamine [letter]," British Journal of Clinical Pharmacology 22(5): 620-22 (1986).	☐
	4	DESIR et al. "Ritodrine increases plasma melatonin in women," Lancet 1(8317):184-85 (1983).	☐
	5	GARDEET al. "8-methoxypsoralen increases daytime plasma melatonin levels in humans through inhibition of metabolism," Photochemistry and Photobiology 60(5):475-80 (1994).	☐
	6	GARRATT et al. (1995). "Mapping the Melatonin Receptor. 3. Design and Synthesis of Melatonin Agonists and Antagonists Derived from 2-phenyltryptamines," Journal of Medicinal Chemistry 38(7):1132-39.	☐
	7	GROTA et al. "Psoralen increases melatonin levels without ultraviolet light." Annals of the New York Academy of Sciences 453:385-87(1985).	☐
	8	KRAUCHI et al. "Evidence for a phase advance in circadian temperature regulation after acute melatonin and a melatonin agonist (S-20098)," Sleep Research 24: 526 (1995).	☐
	9	LE GOUIC et al. "Effects of both a melatonin agonist and antagonist on seasonal changes in body mass and energy intake of the garden dormouse," International Journal of Obesity 20(7): 661-67(1996).	☐
	10	MARTINET et al. "Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent," Pharmacology Biochemistry and Behavior 54:713-18 (1996)	☐
	11	MATHE-ALLAINMAT et al. "Synthesis of 2-amido-2,3-dihydro-1H-phenelene derivatives as new conformationally restricted ligands for melatonin receptors," Journal of Medicinal Chemistry 39(16): 3089-95 (1996)	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10642844
	Filing Date	2003-08-18
	First Named Inventor	Lewy
	Art Unit	1614
	Examiner Name	Royds, Leslie A.
	Attorney Docket Number	90-559-T

	12	OXENKRUGET al "Single dose of tranylcypromine increases human plasma melatonin," Biological Psychiatry 21: 1081-85 (1986).	☐
	13	PALAZIDOU et al "Noradrenaline uptake inhibition increases melatonin secretion, a measure of noradrenergic neurotransmission, in depressed patients," Psychological Medicine 22(2):309-15 (1992).	☐
	14	REDMAN et al. "Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms," Psychopharmacology (Berl) 118(4):385-90 (1995).	☐
	15	SACK "Desmethylimipramine treatment increases melatonin production in humans," Biological Psychiatry 21:406-10 (1986).	☐
	16	SOUETRE et all. "5-Methoxypsoralen increases the plasma melatonin levels in humans," Journal of Investigative Dermatology 89(2):152-55 (1987).	☐
	17	SPASONI et al. "2-Substituted 5-methoxy-Nacyltryptamines: synthesis, binding affinity for the melatonin receptor, and evaluation of the biological activity," Journal of Medicinal Chemistry 36(25):4069-74 (1993).	☐
	18	TARZIA at al. "Design and synthesis of melatonin receptor agonists and antagonists," Farmaco 55(3):184-87(2000).	☐
	19	TARZIA et al. "1-(2-Alkaneamidoethyl)-6-methoxyindole derivatives: A new class of potent indole melatonin analogues. Evaluation of the biological activity," Journal of Medicinal Chemistry 40(13):2003-10 (1997).	☐

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.